SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Don S.Boller who wrote (29226)8/31/1999 10:14:00 PM
From: bob zagorin  Read Replies (1) | Respond to of 32384
 
IMHO, LGND is still a late development stage bio moving toward becoming a pharm. At this point, test results on major technology platforms are far more important than timing on sales of two acquired products. LGND deserves criticism for letting these timelines slip but NBD. LGND has plenty of cash drawn down at $14 / share from Elan. i've got allthe LGND I can handle right now but IMHO this is overreaction by both the analysts and investors.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News